OSEIN does not provide investment advice, and the information contained in this memo should not be solely relied upon for making investment decisions. Investors are encouraged to conduct their own due diligence and seek professional advice before making any investment. OSEIN does not assume any liability or responsibility for investment outcomes. Additionally, AI was used to review, synthesize, and prepare the following information.
Investing in early-stage and angel investments is inherently risky, and investors should be aware that they may lose their entire investment. By proceeding with any investment, investors acknowledge and assume these risks and understand that the outcomes can be unpredictable and may not result in financial gain.
Website: https://www.callali.ly/
UK Company House Page: https://find-and-update.company-information.service.gov.uk/company/13417472
LinkedIn: https://www.linkedin.com/company/calla-lily-clinical-care/?originalSubdomain=uk
Venture360 Page: https://ohiostateearlyinvestornetwork.venture360.co/companies/140361-calla-lily-clinical-care
Calla Lily Clinical Care is a London-based women's health medical technology company developing Callavid, a patented intravaginal drug-device delivery platform designed to improve the administration of medications and hormones. The company's initial product combines micronized progesterone with its proprietary delivery device to improve luteal phase support during in vitro fertilization (IVF) and reduce the risk of threatened miscarriage by providing leak-free, consistent drug delivery. Beyond reproductive medicine, the platform is designed to support a broad pipeline of localized and systemic therapeutics across women's health, infectious disease, oncology, hormone replacement therapy, and biologics.